JAMA network open

Long-Term Health Care Costs of Using GLP-1 Drugs Compared to Weight-Loss Surgery

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective interventions for obesity and type 2 diabetes.

  • Obesity and type 2 diabetes contribute significantly to global health issues and economic costs.
  • The long-term effects of BMS and GLP-1RAs on health care utilization costs are not fully known.
  • Both interventions may help manage obesity and diabetes, but their impact on overall health expenses is still under investigation.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Conflict of Interest Disclosures: Dr Arbel reported receiving grants from Horizon Europe. Dr Reges reported receiving grants from the Israel Science Foundation and Israel–Ministry of Innovation, Science and Technology outside the submitted work. Dr Dicker reported receiving grants, personal fees, and nonfinancial support from Novo Nordisk, Lilly, and Boehringer Ingelheim; and personal fees from Rafa, AstraZenca, and Roche outside the submitted work. Dr Lavie reported receiving grants from the Israel Science Foundation outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
6 days ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
1 week ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
3 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
4 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
5 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
6 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
7 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
8 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief